AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2014
Feb 4, 2014
30583_dirs_2014-02-04_e5914d55-a27c-44ac-bbaa-cb9ae968a61f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2014-02-03
Reporting Person: FUCHS HENRY J (EVP, Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-03 | Common Stock | M | 10000 | $21.51 | Acquired | 52350 | Direct |
| 2014-02-03 | Common Stock | S | 10000 | $67.6966 | Disposed | 42350 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-02-03 | Stock Option (right to buy) Common Stock | $21.51 | M | 10000 | Disposed | 2020-05-11 | Common Stock (10000) | Direct |
Footnotes
F1: Transaction made pursuant to 10b5-1 trading plan executed on December 13, 2013.
F2: The price in column 4 is weighted average price. The price actually received ranged from $66.96 to $69.08. The reporting person will provide to the isuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Options vest 6/48ths on November 12, 2010 and 1/48th on the 12th of each month thereafter.
F4: Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.